[{"orgOrder":0,"company":"Ignota Labs","sponsor":"Montage Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ignota Labs","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ignota Labs \/ Montage Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ignota Labs \/ Montage Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Ignota Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The funding will be used to expand the pipeline by acquiring additional distressed assets and for advancement into early-stage clinical trials of Ignota's first asset, a PDE9A inhibitor.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 26, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Montage Ventures

                          Deal Size : $6.9 million

                          Deal Type : Financing

                          blank